1Reale C ,Turkiewicz AM ,Reale CA. Antalgic treatment of pain associated with bone metastases[ J]. Crit Rev Oncol Hematol,2001,37 ( 1 ) : 1.
2Coleman RE, Purehit OP. Osteoclast inhibition for the treatment of bone metastases [ J]. Cancer Treat Rev, 1993,19 ( 1 ) :79.
3Green JR, Muller K, Jaeggi KA. Preclinical Pharmacology of GCP 42 466, a new potent, heterocyclic bisphosphonate compound [J]. Bone Miner Res,1994,9(5) :745.
4Wellington K, Goa KL. Zoledrenic acid : a review of its use in the management of bone metastases and hypercalcaemia of malignancy [J]. Drugs,2003,63 (4) :417.
5Croucher P, Jagdev S, Coleman R. The anti-tumor potential of zoledronic acid [J]. Breast Cancer,2003,12 ( Suppl 2) : S30.
6Rosen LS,Gordon D,Kaminski M,et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced muhiplemyeloma or breast carcinoma, a randomized, double-blind, multicenter, comparative trial[J]. Cancer,2003,98 (8) : 1735.
7Algur E, Roger MD, Macklis M, et al. Synergistic Cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines[J]. Int J Radiat Oncol Biol Phys,2005,61 (2) :535.
